EA201991304A1 - 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени - Google Patents

5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени

Info

Publication number
EA201991304A1
EA201991304A1 EA201991304A EA201991304A EA201991304A1 EA 201991304 A1 EA201991304 A1 EA 201991304A1 EA 201991304 A EA201991304 A EA 201991304A EA 201991304 A EA201991304 A EA 201991304A EA 201991304 A1 EA201991304 A1 EA 201991304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
thiazolidine
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
EA201991304A
Other languages
English (en)
Russian (ru)
Inventor
Мария Пилар Пискуэта Лаланса
Марк Мартинель Педемонте
Original Assignee
Минорикс Терапьютикс С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Минорикс Терапьютикс С.Л. filed Critical Минорикс Терапьютикс С.Л.
Publication of EA201991304A1 publication Critical patent/EA201991304A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201991304A 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени EA201991304A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382584 2016-12-01
PCT/IB2017/057587 WO2018100557A1 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
EA201991304A1 true EA201991304A1 (ru) 2019-12-30

Family

ID=57517838

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991304A EA201991304A1 (ru) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени

Country Status (20)

Country Link
US (1) US11938122B2 (ko)
EP (1) EP3548026B1 (ko)
JP (1) JP7040798B2 (ko)
KR (1) KR102595034B1 (ko)
CN (1) CN110022877B (ko)
AU (1) AU2017370003B2 (ko)
BR (1) BR112019011334A2 (ko)
CA (1) CA3044364A1 (ko)
CY (1) CY1124116T1 (ko)
DK (1) DK3548026T3 (ko)
EA (1) EA201991304A1 (ko)
ES (1) ES2867300T3 (ko)
HR (1) HRP20210576T1 (ko)
HU (1) HUE054346T2 (ko)
LT (1) LT3548026T (ko)
MX (1) MX2019006066A (ko)
PL (1) PL3548026T3 (ko)
PT (1) PT3548026T (ko)
SI (1) SI3548026T1 (ko)
WO (1) WO2018100557A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054346T2 (hu) 2016-12-01 2021-08-30 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére
WO2019234664A1 (en) 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
CA3180351A1 (en) 2020-04-30 2021-11-04 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
HUT68370A (en) * 1991-04-11 1995-06-28 Takeda Chemical Industries Ltd Thiazolidine derivatives, pharmaceutical compositions containing them and process for their production
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20050107450A1 (en) 2001-12-21 2005-05-19 Brown Kathleen K. Dosing regimen for ppar-gamma activators
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
GB0510469D0 (en) 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
MX356584B (es) 2006-03-16 2018-06-05 Metabolic Solutions Dev Co Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
PT3388064T (pt) * 2014-04-02 2021-05-14 Minoryx Therapeutics S L Derivados de 2,4-tiazolidinediona no tratamento de distúrbios do sistema nervoso central
HUE054346T2 (hu) 2016-12-01 2021-08-30 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-dion nem-alkoholos zsírmáj-betegség kezelésére

Also Published As

Publication number Publication date
WO2018100557A1 (en) 2018-06-07
PL3548026T3 (pl) 2021-08-23
HUE054346T2 (hu) 2021-08-30
CN110022877A (zh) 2019-07-16
MX2019006066A (es) 2019-09-10
KR20190086766A (ko) 2019-07-23
EP3548026A1 (en) 2019-10-09
DK3548026T3 (da) 2021-04-19
KR102595034B1 (ko) 2023-10-26
JP7040798B2 (ja) 2022-03-23
HRP20210576T1 (hr) 2021-05-28
US20200093812A1 (en) 2020-03-26
CA3044364A1 (en) 2018-06-07
LT3548026T (lt) 2021-05-25
AU2017370003A1 (en) 2019-06-06
CY1124116T1 (el) 2022-05-27
JP2020500868A (ja) 2020-01-16
US11938122B2 (en) 2024-03-26
ES2867300T3 (es) 2021-10-20
SI3548026T1 (sl) 2021-07-30
PT3548026T (pt) 2021-04-22
EP3548026B1 (en) 2021-01-20
BR112019011334A2 (pt) 2019-10-15
CN110022877B (zh) 2023-06-23
AU2017370003B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
CY1124116T1 (el) 5-[[4-[2-[5-(1-υδροξυαιθυλ)πυριδιν-2-υλ]αιθοξυ]φαινυλ]μεθυλ]-1,3-θειαζολιδινο-2,4-διονη για την θεραπεια της μη αλκοολικης λιπωδους νοσου του ηπατος
MX2022007607A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
PE20142292A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PH12015501795A1 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
RU2018140960A (ru) Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4
JP2016519072A5 (ko)
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201491007A1 (ru) Лекарственные составы
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
EA202092954A1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
MX2017013788A (es) Composicion farmaceutica estabilizada.
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
PE20141353A1 (es) Derivado de acido pirrolidin-3-ilacetico
EA201692515A1 (ru) Новая фармацевтическая композиция на основе софосбувира и рибавирина
EA201690762A1 (ru) {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек
EA202091821A1 (ru) Ингибиторы cd73
AR098003A1 (es) Inhibidores de kras g12c